The Serum Damine oxidase (DAO), serum bacterial endotoxin (BT) and D-lactic acid (D-Lac) TNF-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in patients sepsis combined with acute kidney injury after Bexira administration
Serum biomarkers in patients with sepsis
Abstract
Objective: The present investigations were designed to investigate the clinical effectiveness of Bexira in acute kidney injury patients complicated by a septic condition, and further analyze its potential effects on Serum Damine oxidase (DAO), serum bacterial endotoxin (BT) and D-lactic acid (D-Lac) TNF-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in patients, so as to enhance the scientific basis for clinical treatments.
Methods: Between January 2024 and December 2024, 200 patients with sepsis associated with acute kidney injury were admitted to our hospital. These individuals were incorporated into our research cohort. In order to ensure the scientificity and comparability of the study, we used A random number table method to randomly divide these 200 patients into panels A and B, with 100 patients in per group. Group A patients received standard conventional care, including but not limited to anti-infective therapy, nutritional support, and symptomatic management. Group B received additional treatment with Bexira on the basis of group A. All patients enrolled in the study underwent detailed clinical assessments and appropriate medical examinations to ensure the safety and efficacy of the treatment. Prior to treatment, all patients underwent a comprehensive assessment to understand their baseline health status. 7 days after the start of treatment, the changes of intestinal mucosal barrier function, immune function and their prognosis were monitored in both groups. By comparing the two populations before and after treatment, we aim to better understand what factors may affect a patient's recovery process and long-term prognosis.
Results: After 7 days of treatment, we observed significant reductions in diamine oxidase (DAO) levels, bacterial endotoxin (BT) content, and D-lactic acid (D-Lac) concentration in both experimental groups. Especially in group B, the changes of these three biomarkers were more significant, and their values were lower than those of control group A, indicating that the treatment effect of group B was better than that of group A. This variation is of major concern in terms of statistically validity, that is, P<0.05, meaning that the test results could not be regarded as due to chance or error, but could be confirmed as changes in biological indicators caused by effective treatment strategies. These data not only demonstrate the short-term effect of the treatment, but also hint at possible long-term benefits, and warrant further research to explore more about the pharmacological mechanism of effect and clinical application of this agent.
Conclusions: Among the many options for treating sepsis associated with acute kidney injury, the application of Bexira proved to be a significant advance. also enhance the level of the body's immune response, thereby helping to improve the overall health status and prognosis of patients.
References
[2] Hao Y. Analysis of the effect and symptom outcome of continuous blood purification therapy in patients with severe sepsis [J]. Community doctors in China, 2019, 35 (11) : 2. DOI: 10.3969 / j.i SSN. 1007-614 - x. 2019.11.017.
[3] Fu Yaoqing. Efficacy of early CRRT in patients with sepsis complicated with acute kidney injury [J]. The contemporary medical sciences, 2021. DOI: 10.3969 / j.i SSN. 2095-7629.2021.10.059.
[4] Sun X Y, Lu Z Q, Zhang J. The Campaign to Save Sepsis: International Guidelines for the Treatment of Sepsis and Septic Shock (2021) [J]. Chinese Journal of Integrated Traditional and Western Medicine First Aid, 2021, 28(6):645-652.
[5] Qu Z, Zhu Y, Wang M, Li W, Zhu B, Jiang L. Prognosis and Risk Factors of Sepsis Patients in Chinese ICUs: A Retrospective Analysis of a Cohort Database. Shock. 2021 Dec 1;56(6):921-926. doi: 10.1097/SHK.0000000000001784. PMID: 33843790; PMCID: PMC8579969.
[6] Zheng Chunhe, Qu Nan. Effect of early continuous blood purification on immune function, renal function and microcirculation indexes in patients with severe sepsis complicated with acute kidney injury [J]. Electronic Journal of Modern Medicine and Health Research, 2021, 5(9):3.
[7] Li Wanglong, Ye Shaobo, Li He. Continuous blood purification in the treatment of sepsis shock and acute kidney injury in patients with the clinical efficacy of [J]. 2021. The DOI: 10.16458 / j.carol carroll nki. 1007-0893.2021.16.078.
[8] Ding Chunlong, Wang Yuhai, Yang Likun. Role of serum D-lactic acid, bacterial endotoxin and diamine oxidase in evaluating intestinal mucosal barrier function after traumatic brain injury [J]. The Chinese journal of neurosurgery, 2019, 35 (12) : 4. DOI: 10.3760 / cma. J.i SSN. 1001-2346.2019.12.015.
[9] Bai Zhun, Liu Xuli, Zeng Weizhong. Effects of different doses of CRRT on immune function, intestinal mucosal barrier function and prognosis in patients with severe sepsis [J]. Hebei medicine, 2020. DOI: 10.3969 / j.i SSN. 1002-7386.2020.12.024.
[10] Huang Liying, Liu Tao. Immune cell aging performance and the research progress of immune function change [J]. Chinese cell and stem cell magazine: electronic, 2020, 10 (2) : 6. DOI: 10.3877 / cma. J.i SSN. 2095-1221.2020.02.009.
[11] Gao Lin. Effects of early continuous renal replacement therapy on inflammatory mediators and immune function in patients with severe sepsis [J]. Medical equipment, 2020 (3) : 2. DOI: CNKI: SUN: YLZB. 0.2020-03-040.
[12] Lei Zhong, Zhang Kailong and Yin Yan. Effect of continuous renal replacement on serum inflammatory factors in patients with sepsis complicated with acute kidney injury [J]. Chinese Journal of Integrative Nephropathy, 2021, 22(9):823-824. (in Chinese)
[13] Zhang Zuqin. Effect of urinary volume change on prognosis of patients with acute kidney injury in septic patients with continuous renal replacement [J]. Chinese medical science, 2021, 11 (12) : 5. DOI: 10.3969 / j.i SSN. 2095-0616.2021.12.047.
[14] Manrique-Caballero C L, Del Rio-Pertuz G, Gomez H. Sepsis-associated acute kidney injury[J]. Critical Care Clinics, 2021, 37(2): 279-301.
[15] Poston J T, Koyner J L. Sepsis associated acute kidney injury[J]. Bmj, 2019, 364.
[16] Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment[J]. Kidney international, 2019, 96(5): 1083-1099.
[17] Gómez H, Kellum J A. Sepsis-induced acute kidney injury[J]. Critical care nephrology, 2019: 524-533. e3.
[18] You XY, Zhang HY, Han X, Wang F, Zhuang PW, Zhang YJ. Intestinal mucosal barrier is regulated by intestinal tract neuro-immune interplay[J]. Frontiers in Pharmacology, 2021, 12: 659716.
[19] Xie SZ, Liu B, Ye HY, Li QM, Pan LH, Zha XQ. Dendrobium huoshanense polysaccharide regionally regulates intestinal mucosal barrier function and intestinal microbiota in mice[J]. Carbohydrate polymers, 2019, 206: 149-162.
[20] Xie SZ, Shang ZZ, Li QM, Zha XQ, Pan LH, Luo JP. Dendrobium huoshanense polysaccharide regionally regulates intestinal mucosal barrier function and intestinal microbiota in mice[J]. Carbohydrate polymers, 2019, 206: 149-162.
[21] Yang S, Yu M. Role of goblet cells in intestinal barrier and mucosal immunity[J]. Journal of inflammation research, 2021: 3171-3183.
[22] Ren Z, Guo C, Yu S, Zhu L, Wang Y, Hu H, et al. Progress in mycotoxins affecting intestinal mucosal barrier function[J]. International journal of molecular sciences, 2019, 20(11): 2777.
[23] Wang D, Sun T, Liu Z. Sepsis-associated acute kidney injury[J]. Intensive Care Research, 2023, 3(4): 251-258..
[24] Thompson K, Venkatesh B, Finfer S. Sepsis and septic shock: current approaches to management[J]. Internal Medicine Journal, 2019, 49(2): 160-170.
[25] Ostermann M, Bellomo R, Burdmann EA, Doi K, Endre ZH, Goldstein SL, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference[J]. Kidney international, 2020, 98(2): 294-309.
[26] He J, Xiao Z, Zhou X, Cao J. Comparison of different modalities of continuous renal replacement therapy with regional sodium citrate anticoagulation in paediatric patients[J]. The International Journal of Artificial Organs, 2022, 45(12): 997-1005.
[27] Li L, Bai M, Zhang W, Zhao L, Yu Y, Sun S. Regional citrate anticoagulation versus low molecular weight heparin for CRRT in hyperlactatemia patients: A retrospective case-control study[J]. The International Journal of Artificial Organs, 2022, 45(4): 343-350.
[28] Jonckheer J, Spapen H, Malbrain MLNG, Oschima T, De Waele E. Energy expenditure and caloric targets during continuous renal replacement therapy under regional citrate anticoagulation. A viewpoint[J]. Clinical nutrition, 2020, 39(2): 353-357.
[29] CC Liang, HC Yeh, PS Chen, CC Kuo, HY Chiang. 8. Sepsis-Associated Acute Kidney Injury and Acute Kidney Disease: A 15-Year Cohort Study of 4,226 Adult Sepsis Inpatient Survivors at a Tertiary Medical Center in Taiwan[C]//Open Forum Infectious Diseases. US: Oxford University Press, 2021, 8(Supplement_1): S6-S7.
[30] Fan G, Chen M J, Wei J. Involvement of phosphatase and tensin homolog-induced putative kinase 1/Parkin-mediated autophagy in angiotensin II-induced cardiac hypertrophy in C57BL/6 mice[J]. Journal of International Medical Research, 2020, 48(5): 0300060519896143.
Copyright (c) 2025 Handong Huang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.